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Health Insurance Service of Korea. All costs were measured in Korean won (KRW) and 
converted to US dollars (USD) using 2014 official exchange rate (1USD= 1,053.22KRW). 
Discount rate of 5% was applied to cost and effectiveness. Results: Based on com-
plete cytogenetic response rates at 12 month, Imatinib ($277,971) was less costly 
than Dasatinib ($388,232) and Nilotinib ($445,548). Life-year gains of Dasatinib (15.18 
LYs), were superior to other TKIs (Imatinib: 14.52 LYs, Nilotinib: 15.13 LYs), but ICER 
was $167,010 per LYs which far exceeds current willingness to pay level ($28,484) 
in Korea. Applying major molecular response rates at 12 month, the most effec-
tive strategy was Nilotinib ($416,513, 14.76 LYs), but its cost was the highest among 
others: Dasatinib ($365,602, 14.47 LYs) and Imatinib ($300,490, 13.8 LYs). The ICER of 
Dasatinib and Nilotinib was $98,483 and $170,431 per LYs respectively compared to 
Imatinib. ConClusions: Given the current willingness to pay level of $28,959 in 
Korean setting, Imatinib (400 mg) was found out to be the most cost-effective strategy 
compared to Dasatinib (100mg) and Nilotinib (300 mg).
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Cost-EffECtivENEss of DirECtly MailED fobt Kits to PrEvious 
rEsPoNDErs bEiNg rECallED for sCrEENiNg
Mittmann N1, Hassan S2, Patel J1, Tinmouth J1
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Toronto, ON, Canada
objeCtives: To conduct a cost-effectiveness analysis to evaluate whether the addi-
tion of a fecal occult blood test (FOBT) kit to a mailed invitation for recall compared 
to a mailed invitation for recall alone increases participation among patients who 
had responded previously to a mailed invitation in screening for colorectal cancer 
(CRC). Methods: The perspective of the analysis will be that of the cancer agency 
in Ontario, Canada. Eligible patients (responders to the initial pilot study invita-
tion, FOBT negative, and now due for repeat screening) from 61 physicians were 
randomly allocated to one of the two interventions: (1) Mailed FOBT kit and mailed 
invitation for recall from their family physician (intervention group) OR (2) mailed 
invitation alone for recall (control group). Health system and program resources and 
costs associated with each group will be identified and quantified. Resources will 
be stratified into fixed costs (initial set-up costs including document development, 
programming for ongoing maintenance, etc.), variable or recurrent costs (costs of 
the kit, administrative costs, physician visits etc.) and staff costs (call centre sup-
port personnel and business analyst). Results: There are a total of 431 patients in 
the intervention group and 452 patients in the control group. Overall costs for each 
group will be determined, and the cost per patient will be reported. Cost drivers 
will be identified by conducting a series of univariate sensitivity analyses, including 
reducing the cost of the kit and using different assumptions for kit wastage. The 
results will show whether the addition of the FOBT kit to the mailed invitation is 
cost effective when compared to a mailed invitation only. ConClusions: This cost 
effectiveness analysis will help in determining effective strategies for screening 
programs that are needed to reduce CRC mortality at a population level.
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objeCtives: To assess the clinical and cost effectiveness of mammography for 
breast cancer screening in India Methods: A systematic literature search was 
conducted in all the available scientific databases - Cochrane library, MEDLINE, 
PUBMED Science Direct, EMBASE, SCOPUS and Google Scholar for relevant studies. 
We identified 31 studies and literature filter started by scanning titles; abstracts as 
well as the content of the articles according to Inclusion criteria; finally 12 studies 
were included in quantitative synthesis (Meta analysis). We estimated risk of bias 
using Cochrane collaborating guidelines. Results: Review Manager 5.2 was used 
to do the data analysis and results are expressed in legible diagrams, considering 
all 12 studies with data from 4047721 participants, Risk Ratio was calculated (RR): 
0.71 (95% confidence Interval, CI: 0.67, 0.75). ConClusions: Annual screening 
of female population above 30 years of age could reduce breast cancer associ-
ated mortality by 29% mainly due to early detection of breast cancer detection 
and subsequent early treatment pathways. The cost effectiveness is about Rs. 
19520/- per life year gained which is an excellent social return on investment on 
this technology.
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objeCtives: Evaluation of cost-effectiveness and cost-utility of afatinib in 
patients with non-small cell lung cancer (NSCLC) with deletion in 19th exon of epi-
dermal growth factor receptor (EGFR) gene in 1st-line therapy. Methods: Markov 
modeling was implemented to simulate clinical and economical outcomes of dif-
ferent strategies in treatment of naïve patients with NSCLC over 18 years old based 
on results of randomized clinical trials LUX-Lung 3 and LUX-Lung 6. Direct medical 
costs were considered. The time horizon of the analysis – 10 years. Compared 
drugs: afatinib, erlotinib, gefitinib and combination cisplatin/pemetrexed. Results 
were expressed in terms of quality-adjusted life years (QALY), life years (LY) gained 
and ICER (QALY). Results: Afatinib used as 1st-line treatment in patients with 
inform this model are US-specific and would require adaptation to be generalizable 
elsewhere. Depending on the threshold used by the decision maker, RAM+DOC 
may be a cost-effective option for the overall and nonsquamous NSCLC population.
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CoMParativE EffiCaCy aND Costs of trEatMENt sEquENCEs iN 
MEtastatiC CastratioN rEsistaNt ProstatE CaNCEr
Pérez-Alcántara F1, Martínez Llinàs D1, Maroto JP2, Gallardo E3, Subirà R4, Rubio M4
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objeCtives: Abiraterone (ABI) and enzalutamide (ENZ) have been recently approved 
for the treatment of docetaxel (DOC)-naïve metastatic castration-resistant prostate 
cancer (mCRPC) but the cost-effectiveness associated with sequencing of these 
agents remains unclear. The objective of this study was to compare the efficacy 
and drug costs of different treatment sequences considering the loss of efficacy 
associated to subsequent treatments in mCRPC patients. Methods: Median overall 
survival (OS) and costs were estimated for the following sequences: (A) ABI-DOC-
CBZ; (B) ABI-DOC-ENZ; (C) ENZ-DOC-CBZ and (D) ENZ-DOC-ABI. OS and duration 
of treatment (DoT) estimates were based on data from clinical trials and adjusted 
according to literature review and expert clinical opinion, to account for potential 
efficacy loss after ABI or ENZ exposure as follows: DOC -10%; CBZ -10%; ENZ -40%; 
ABI -50%. The cost analysis included only drug costs and was undertaken from the 
perspective of the Spanish National Healthcare System. Incremental cost-effective-
ness ratios (ICERs) were calculated in terms of cost per life year gained (LYG) for 
the following comparisons: A-vs-B and C-vs-D. Uncertainties around efficacy and 
DoT assumptions were explored in a sensitivity analysis. Results: In the base 
case scenario, median OS estimates for patients treated with sequences A, B, C and 
D were 40.1, 37.5, 34.8 and 29.1 months, with respective costs of € 68,967, € 62,228, 
€ 60,766 and € 50,952. The ICERs were € 31,712/LYG for A vs B and € 20,697/LYG for C 
vs D. When reduction rates were applied only to OS but were not considered their 
influence on DoT, treatment sequences containing third-line CBZ were dominant vs 
sequences containing ENZ or ABI. ConClusions: Sequences containing third-line 
CBZ were more effective than sequences containing third-line ABI or ENZ. Third-line 
CBZ after ABI-DOC or after ENZ-DOC could be considered as cost-effective compared 
to third-line ABI or ENZ.
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thE Cost–EffECtivENEss of rEgorafENib iN thE trEatMENt of PatiENts 
With MEtastatiC ColorECtal CaNCEr (MCrC) Who havE ProgrEssED 
aftEr staNDarD thEraPiEs iN turKEy
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objeCtives: To evaluate the cost-effectiveness of regorafenib compared to 
the standard of care (SoC), in the treatment of metastatic colorectal cancer in 
previously treated patients. Methods: A cohort partition model demonstrating the 
progression of mCRC patients towards death and evaluating clinical and economi-
cal outcomes was adapted to the Turkish setting. Event and mortality rates were 
derived from the CORRECT clinical trial. An expert panel, with the participation of 
experts in colorectal cancer, was established for the adaptation of clinical data to 
Turkish practice. The analysis was undertaken from payer perspective. The time 
horizon was taken as life time period. Costs of each health state included year 2015 
local costs of medications, monitoring and events (TL/EUR currency rate was set 
at 2.9274; mid 2015). Incremental cost effectiveness ratios (ICER) per life year (LY) 
were calculated. Willingness-to-pay (WTP) threshold was set to two times of the 
local gross domestic product per capita per life years saved (adapted from World 
Health Organization definition) and was calculated as 18,481EUR. One-way sensi-
tivity analyses were conducted to test the robustness of the model. Results: The 
total cost of regorafenib was 2,173EUR higher compared to SoC. Regorafenib was 
associated with increment of 0.153 LYs, leading to an ICER of 14,188EUR/LY gained. 
Life years gained were 0.215 and 0.221 years in patients with wild type K-ras muta-
tion and patients with less than 4 lines of treatment, respectively. Accordingly, ICER 
values were lower (10,280EUR and 8,308EUR) than overall group in these subgroups. 
Sensitivity analyses showed that the cost-effectiveness results are fairly insensitive 
to most inputs. ConClusions: Regorafenib, given its improvement in progression 
free survival and overall survival, and ICER values below WTP threshold, is suggested 
to be a cost-effective alternative in the treatment of metastatic colorectal cancer in 
previously treated patients in Turkey.
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Cost-EffECtivENEss of first-liNE tyrosiNE KiNasE iNhibitors (tKis) iN 
NEWly DiagNosED ChroNiC MyEloiD lEuKEMia (CMl) PatiENts iN KorEa: 
CoMParisoN of DasatiNib (100Mg), NilotiNib (600Mg) aND iMatiNib 
(400Mg)
Shin M, Shin S, Lee JY, Kim J, Park J, Kwon H
National Evidence based Health-care Collaborating Agency, Seoul, South Korea
objeCtives: This study aims to evaluate cost effectiveness of currently available first-
line TKIs, Dasatinib (100mg), Nilotinib (600 mg) and Imatinib (400mg), in treatment of 
newly diagnosed CML patients in Korea. Methods: We developed a Markov model 
model composed of four health states: response in chronic-phase (CP), no-response 
in CP, accelerated or blastic phase (AP/BP) and Death. Progression rate to AP/BP is 
assumed to be dependent on the presence of cytogenetic or molecular response to 
TKI at 12 month. Clinical effectiveness were obtained from DASISION and ENESTnd 
trials. In terms of cost, only direct medical costs (e.g. outpatient, hospitalisation and 
medication costs) with 5% of patient copayment were included into the study. Average 
medical cost of CML patients were calculated using claims data from the National 
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first and second line therapy for advanced NSCLC patients with EGFR mutation by 
China guideline for treatment of primary lung cancer. This study aims to system-
atically evaluate cost-effectiveness of geftinib in China. Methods: A systematic 
review of cost-effectiveness of geftinib in China was conducted. We searched for 
Chinese literatures in “CNKI”, “Wanfang data”, and “VIP.com”. Search pattern was 
“gefitinb” AND “cost or economic or expense” in abstract. Publication deadline was 
May 31th, 2015. Cost analysis (CA), cost-effectiveness analysis (CEA), cost-utility 
analysis (CUA), and cost-benefit analysis of gefitinib were included. NoteExpress 
2.7 was used for literature management. Results: We retrieved abstracts of 39, 42 
and 20 from CNKI, Wanfang and VIP respectively. Then 59 abstracts were selected 
to conduct abstract analysis after deleting duplications, followed by 15 selected to 
full-text analysis. At last, 7 studies were included. For first line treatment compari-
son, 1 CUA evaluating gefitinib and chemotherapy (paclitaxel+carboplatin) shows 
geftinib dominates the chemotherapy with an ICER of ¥-13499.7/QALY. For second 
line comparison, 2 CAs show costs of geftinib are much lower than comparators, 3 
CEAs show gefitinib is cost effective compared to erlotinib with much lower cost-
effectiveness ratios, and 1 CEA shows docetaxel is dominated by gefitinib, which 
has much lower costs(¥23022 vs. ¥24390) and higher objective response rate(26.90% 
vs. 10.30%). ConClusions: Our systematic review demonstrates that Gefitinib is 
cost effective in both first and second line treatment of NSCLC in a Chinese setting.
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rEsults of a DutCh Cost-EffECtivENEss MoDEl of raDiuM-223 iN 
CoMParisoN to CabazitaxEl, abiratEroNE, aND ENzalutaMiDE iN 
PatiENts With MEtastatiC CastratioN rEsistaNt ProstatE CaNCEr 
PrEviously trEatED With DoCEtaxEl
Gaultney J1, Baka A1, Leliveld-Kors A2, Noordzij W2, Wyndaele D3, De Meyer C4
1Mapi Group, Houten, The Netherlands, 2UMC Groningen, Groningen, The Netherlands, 3Catharina 
Ziekenhuis Eindhoven, Eindhoven, The Netherlands, 4Bayer BV, Mijdrecht, The Netherlands
objeCtives: The treatment landscape of metastatic castration resistant prostate 
cancer (mCRPC) has changed with the introduction of novel agents. As little is 
known about their cost-effectiveness, this study investigates the cost-effectiveness 
of radium-223 versus cabazitaxel, abiraterone and enzalutamide in Dutch mCRPC 
patients previously treated with docetaxel. Methods: A cost-effectiveness analy-
sis was conducted utilizing efficacy, symptomatic skeletal event (SSE) and safety 
data obtained from indirect treatment comparisons. As SSE data are unavailable 
for cabazitaxel, we conservatively assumed these to be identical to radium-223. A 
Markov model combined these clinical inputs with Dutch-specific resource use 
and costs for mCRPC treatment. Total quality-adjusted-life-years (QALYs) and costs 
were calculated over a 5-year horizon. Analyses were performed from a societal 
perspective. Results: Radium-223 is associated with € 4,535 and € 5,905 lower 
lifetime costs and a difference of -0.004 and 0.02 QALYs compared to cabazitaxel 
and abiraterone, respectively. Sensitivity analyses reveal a 59% (78%) chance of 
radium-223 being cost-effective compared to cabazitaxel (abiraterone) at a € 80,000 
willingness to pay (WTP) threshold, the informal Dutch threshold. Compared to 
enzalutamide, radium-223 is associated with a slightly lower QALY gain (-0.06) and 
€ 7,255 lower lifetime costs, resulting in only a 19% chance of enzalutamide being 
cost-effective compared to radium-223 at a € 80,000 WTP threshold. Sensitivity 
analyses reveal a 74%, 80% and 78% chance of radium-223 being cost-saving com-
pared to cabazitaxel, abiraterone and enzalutamide, respectively.Radium-223’s lower 
lifetime costs compared to abiraterone and enzalutamide are driven by less drug 
costs and prevention of expensive SSE’s. Compared to cabazitaxel, radium-223’s 
savings are driven by fewer costs of the drug, administration and adverse event 
treatment. ConClusions: Our model shows that while QALY gains are in the same 
ballpark (a maximum absolute difference of 0.06 QALY), radium-223 is a cost-saving 
treatment compared to cabazitaxel, abiraterone and enzalutamide in Dutch mCRPC 
patients previously treated with docetaxel.
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ECoNoMiC EvaluatioN of PEgfilgrastiM as ProPhylaxis for fEbrilE 
NEutroPENia iN PatiENts With soliD tuMors or lyMPhoMa rECEiviNg 
ChEMothEraPy iN MExiCo
Alva ME1, Carlos F2, Espinosa K2, Barbosa V3, Naranjo M3
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objeCtives: Febrile neutropenia (FN) is a common side effect of systemic chemo-
therapy associated with significant morbidity, mortality, detrimental quality of life 
and high costs. Most FN events occur in the first cycle. Guidelines recommend 
the prophylactic use of a recombinant human granulocyte colony-stimulating fac-
tor (G-CSF) in patients receiving chemotherapy if risk of FN ≥ 20%. We aimed to 
assess the cost-effectiveness of different G-CSF primary prophylactic regimens in 
Mexico. Methods: A decision model allowed comparison of expected costs and 
outcomes after three competing interventions as prophylaxis: Pegfilgrastim 6mg 
once (PegFGT); filgrastim 300μ g daily during 6 days (FGT-6d) or 3 days (FGT-3d). 
Time-horizon was 21 days (i.e., first cycle). Direct medical costs comprising acquisi-
tion of G-CSF plus ambulatory/inpatient medical care derived from FN were ana-
lyzed under the perspective of Mexican public health system and expressed in 
2015 dollars (USD). Clinical outcomes included frequency of FN events and deaths 
attributable to FN. Published literature and indirect treatment comparisons were 
used for estimating the effectiveness for each intervention. Costs parameters were 
based on local sources. Deterministic and probabilistic sensitivity analyses were 
conducted. Results: PegFGT was the least costly strategy (USD$1,473) leading to 
overall savings of USD$103 (6.6%) and USD$327 (18.2%) when compared to FGT-6d 
and FGT-3d, respectively. The expected number of FN events and deaths caused by 
FN were also lower with PegFGT (99; 11) than with FGT-6d (241; 26) or FGT-3d (285; 31), 
leading to a lower cost of treatment. Based on the cost-effectiveness results, PegFGT 
was the least costly option in around 89% of the simulations generated through 
probabilistic sensitivity analysis. ConClusions: A single dose of pegfilgrastim 
given instead of administering daily doses of filgrastim for 3 or 6 days leads to better 
NSCLC with Del 19 mutation increased quality-adjusted life years (QALY) by 0,354, 
0,665 and 0,670 QALY and overall survival by 0,61, 0,99 and 0,95 years in compari-
son with erlotinib, gefitinib and combination cisplatin/pemetrexed respectively. 
The total costs of therapy for compared drugs were: afatinib – 1 917 425 rub., 
erlotinib – 1 544 852 rub., gefitinib – 1 205 353 rub. and cisplatin/pemetrexed – 1 
203 865 rub. The ICERs were 1 052 934, 1 067 116 и 1 064 708 rubles in comparison 
with erlotinib, gefitinib and combination cisplatin/ pemetrexed respectively per 
QALY. ConClusions: Afatinib was demonstrated to have the highest efficiency 
in terms of overall survival and QALY. Direct costs associated with afatinib were 
the highest because of afatinib superior efficiency. Afatinib was shown to be 
the cost-effective strategy in 1st-line treatment of metastatic NSCLC with Del 
19 gene mutation as willingness to pay threshold (1 455 741,77 rubles) was not 
exceeded.
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stuDy oN Cost-EffECtivENEss aNalysis for MultiPlE MyEloMa 
trEatMENt: a systEMatiC rEviEW of litEraturE froM 2004-2014
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objeCtives: Ministry of Health, Labour and Welfare of Japan aims for the intro-
duction of Health Technology Assessment in FY2016. Compared to foreign coun-
tries, a lack of resources for conducting the analysis has been pointed out in 
Japan. However, pharmaceutical and medical device industries are urged to seek 
practical approaches utilizing best available resources. The objective of this study 
was to review articles for cost-effectiveness studies of multiple myeloma (MM) 
and to evaluate analytical approaches that can be applied to Japanese environ-
ment. Methods: The literature search was conducted in MEDLINE and JDream 
III. Inclusion criteria are studies of 1) chemotherapy for MM, 2) cost-effective-
ness analysis (CEA), 3) published in the past 10 years. Studies were assessed for 
the followings: country, model structure and simulation method, time horizon, 
perspective, source of key parameters, results, and key drivers determined from 
sensitivity analysis. Results: Six studies were reviewed in details. Markov (2 
articles) and discrete event simulation (2 articles) models were adopted, and 
transition probabilities among states were calculated from progress-free sur-
vival and overall survival obtained from clinical trials. Costs for chemotherapy 
were based on literature or expert opinion. Utility scores were assessed along 
with clinical trials (2 articles) or referred to other studies (3 articles). Inclusion of 
disutility of adverse events varied among studies. Parameters which became key 
drivers in those analyses were also different between studies. ConClusions: 
Data collection methods adopted in prior studies were applicable to CEA for MM 
treatment in Japan. Cost data can be obtained not only from questionnaire sur-
vey to doctors but commercial database. Because evidence on utility scores of 
Japanese population is still limited, further studies will be needed in Japanese 
patients.
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Cost EffECtivENEss of CEtuxiMab iN first liNE trEatMENt of ras 
WilD-tyPE MEtastatiC ColorECtal CaNCEr iN thE uK: a suMMary of 
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aND CarE ExCEllENCE (NiCE)
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objeCtives: Colorectal cancer is the fourth most common cancer in the UK and 
the second most common cause of cancer death. NICE recommended the use of 
cetuximab for KRAS wild type mCRC patients with metastasis confined to the liver. 
Recent evidence demonstrated that cetuximab results in significant improvements 
in overall survival in patients with metastatic colorectal cancer (mCRC) expressing 
unmutated NRAS and KRAS exons (RAS wild type), when added to chemotherapy. To 
showcase the improved outcomes of cetuximab treatment and its cost effectiveness, 
a Cost-Utility Analysis was developed for an Health Technology Assessment evi-
dence submission to NICE. Methods: A de Novo Markov model was developed to 
assess the long term outcomes and cost effectiveness of adding cetuximab to either 
FOLFOX or FOLFIRI chemotherapy. The state transition model simulates patients’ 
journey through 5 health states: first, second and third line treatments post disease 
progression, successful surgical resection of liver metastasis with curative intent 
and death. The time horizon was set to 10 years and a 3.5% discount rate was applied 
to both outcomes and costs. Cetuximab list price was used in all analyses. Separate 
analyses were conducted using the licensed weekly cetuximab dose and the fort-
nightly dose typically used in clinical practice in England and Wales. Results: 
The model estimates that cetuximab addition to FOLFOX adds 0.32 QALYs and 0.29 
when added to FOLFIRI. When considering the fortnightly cetuximab dose, the ICER 
for combining cetuximab with FOLFOX is £46,503 per QALY compared to FOLFOX 
alone and £55,971 per QALY when combining cetuximab with FOLFIRI compared to 
FOLFIRI alone. ConClusions: The evidence submission to NICE demonstrated the 
significant improvements in overall survival (OS) in RAS wild type mCRC patients 
compared to standard treatments. The cost effectiveness of cetuximab could be 
deemed favourable especially when considering it as an “End of Life” medicine.
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systEMatiC rEviEW of Cost EffECtivENEss of gEfitiNib iN thE 
trEatMENt of NoN-sMall CEll luNg CaNCEr iN ChiNa
HU C1, Huang L2, Zhao D2, Xu L2
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objeCtives: Lung cancer is the cancer ranking top one in both incidence and mor-
tality among cancers in China. More than 85% of lung cancer patients suffer from 
non-small cell lung cancer (NSCLC). As the first epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor marketed in China, gefitinib was recommended as 
